Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.
AMLX
$33.45
+$12.02 +56.09%

Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Market News
18 Aug 2026
Tony Dante
View Source
Bullish
pluang ai news

Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stock hit a 52-week high of $33.25, boosting market cap to $3.68 billion amid strong trading volume. This breakthrough could advance treatment options for post-weight-loss surgery complications and attract further investor interest.

More News (AMLX)

Amylyx upgraded to Strong Buy after positive phase 3 trial for avexitide in post-bariatric hypoglycemia

Amylyx upgraded to Strong Buy after positive phase 3 trial for avexitide in post-bariatric hypoglycemia

Amylyx Pharmaceuticals received a Strong Buy upgrade following successful phase 3 LUCIDITY trial results for avexitide, which reduced severe hypoglycemic events by 55% in post-bariatric hypoglycemia patients. The drug showed strong statistical signif...

Analyst Insights
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App